協創數據(300857.SZ):香港協創擬在緬甸投設子公司
格隆匯 9 月 30日丨協創數據(300857.SZ)公佈,公司於2020年9月29日召開了第二屆董事會第十次會議,審議通過了《關於香港全資子公司對外投資的議案》,同意全資子公司協創數據技術(香港)有限公司(“香港協創”)在緬甸投資設立全資子公司,此次投資金額不超過50萬美元,由香港協創使用自有資金進行投資。
緬甸協創數據技術有限公司(“緬甸協創”)設立後,將進一步發揮公司的業務、生產、研發資源優勢,同時,本次投資旨在充分利用緬甸人力成本、税收優惠政策及其區位上的相關優勢,有利於提升公司整體競爭力、完善公司海外產能佈局、規避和降低國際貿易形勢影響,實現公司可持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.